SCHEMBL3090955

SCHEMBL3090955

Cc1ccc(-c2c(C#N)c(NCC3CC(O)C3)nc3sc(C(N)=O)c(N)c23)o1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
GAA P10253 2/20 0.54
MEN1 O00255 1/20 0.54
MAPT P10636 1/20 0.54
HPGD P15428 1/20 0.54
KMT2A Q03164 1/20 0.54
LIMK1 P53667 1/20 0.44
EEF2K O00418 13/20 0.43
BRAF P15056 2/20 0.42
HSP90AB1 P08238 1/20 0.42
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
IKBKB O14920 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13885059 0.90 MAPT (0.58) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3656837 0.88 ALDH1A1 (0.40) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3088362 0.87 MAPT (0.50) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3096302 0.86 MAPT (0.49) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3092018 0.85 EEF2K (0.55) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3087584 0.85 MAPT (0.52) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3095689 0.84 MEN1 (0.51) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3099226 0.83 MEN1 (0.51) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3101803 0.82 MAPT (0.49) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL3090523 0.82 MAPT (0.49) ALDH1A1GAAMEN1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234369-A1 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US claimed
CN-101827851-A 5-cyano-thienopyridines for the treatment of tumors MERCK PATENT GMBH 2010-09-08 CN claimed
US-8202882-B2 5-cyanothienopyridines for the treatment of tumours MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-06-19 US disclosed
US-8202882-B2 5-cyanothienopyridines for the treatment of tumours MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-06-19 US disclosed
US-8202882-B2 5-cyanothienopyridines for the treatment of tumours MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-06-19 US disclosed
US-20100234369-A1 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
US-20100234369-A1 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
US-20100234369-A1 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234369-A1 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS TGFBR1, TGFBR2, ACVR1 ALDH1A1 1503/4885GAA 4271/4885MEN1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.